Our data also support the safe use of zoledronic acid as a KATP channel blocker (Maqoud et al., 2021) in the treatment of macroadenoma in C.S. associated with G.O.F. mutations of the ABCC9 and KCNJ8 genes or in cancers in which these subunits were associated with poor prognosis. Here, KCNJ8 is linked to cancer.